31938062|t|The Roles of GSK-3beta in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.
31938062|a|Rationale: Glycogen synthase kinase-3beta (GSK-3beta) plays key roles in metabolism and many cellular processes. It was recently demonstrated that overexpression of GSK-3beta can confer tumor growth. However, the expression and function of GSK-3beta in hepatocellular carcinoma (HCC) remain largely unexplored. This study is aimed at investigating the role and therapeutic target value of GSK-3beta in HCC. Methods: We firstly clarified the expression of GSK-3beta in human HCC samples. Given that deviated retinoid signalling is critical for HCC development, we studied whether GSK-3beta could be involved in the regulation. Since sorafenib is currently used to treat HCC, the involvement of GSK-3beta in sorafenib treatment response was determined. Co-immunoprecipitation, GST pull down, in vitro kinase assay, luciferase reporter and chromatin immunoprecipitation were used to explore the molecular mechanism. The biological readouts were examined with MTT, flow cytometry and animal experiments. Results: We demonstrated that GSK-3beta is highly expressed in HCC and associated with shorter overall survival (OS). Overexpression of GSK-3beta confers HCC cell colony formation and xenograft tumor growth. Tumor-associated GSK-3beta is correlated with reduced expression of retinoic acid receptor-beta (RARbeta), which is caused by GSK-3beta-mediated phosphorylation and heterodimerization abrogation of retinoid X receptor (RXRalpha) with RARalpha on RARbeta promoter. Overexpression of functional GSK-3beta impairs retinoid response and represses sorafenib anti-HCC effect. Inactivation of GSK-3beta by tideglusib can potentiate 9-cis-RA enhancement of sorafenib sensitivity (tumor inhibition from 48.3% to 93.4%). Efficient induction of RARbeta by tideglusib/9-cis-RA is required for enhanced therapeutic outcome of sorafenib, which effect is greatly inhibited by knocking down RARbeta. Conclusions: Our findings demonstrate that GSK-3beta is a disruptor of retinoid signalling and a new resistant factor of sorafenib in HCC. Targeting GSK-3beta may be a promising strategy for HCC treatment in clinic.
31938062	13	22	GSK-3beta	Gene	2932
31938062	40	48	Retinoid	Chemical	MESH:D012176
31938062	63	72	Sorafenib	Chemical	MESH:D000077157
31938062	95	119	Hepatocellular Carcinoma	Disease	MESH:D006528
31938062	132	162	Glycogen synthase kinase-3beta	Gene	2932
31938062	164	173	GSK-3beta	Gene	2932
31938062	286	295	GSK-3beta	Gene	2932
31938062	307	312	tumor	Disease	MESH:D009369
31938062	361	370	GSK-3beta	Gene	2932
31938062	374	398	hepatocellular carcinoma	Disease	MESH:D006528
31938062	400	403	HCC	Disease	MESH:D006528
31938062	510	519	GSK-3beta	Gene	2932
31938062	523	526	HCC	Disease	MESH:D006528
31938062	576	585	GSK-3beta	Gene	2932
31938062	589	594	human	Species	9606
31938062	595	598	HCC	Disease	MESH:D006528
31938062	628	636	retinoid	Chemical	MESH:D012176
31938062	664	667	HCC	Disease	MESH:D006528
31938062	700	709	GSK-3beta	Gene	2932
31938062	753	762	sorafenib	Chemical	MESH:D000077157
31938062	790	793	HCC	Disease	MESH:D006528
31938062	814	823	GSK-3beta	Gene	2932
31938062	827	836	sorafenib	Chemical	MESH:D000077157
31938062	1077	1080	MTT	Chemical	MESH:C070243
31938062	1151	1160	GSK-3beta	Gene	2932
31938062	1184	1187	HCC	Disease	MESH:D006528
31938062	1257	1266	GSK-3beta	Gene	2932
31938062	1275	1278	HCC	Disease	MESH:D006528
31938062	1315	1320	tumor	Disease	MESH:D009369
31938062	1329	1334	Tumor	Disease	MESH:D009369
31938062	1346	1355	GSK-3beta	Gene	2932
31938062	1397	1424	retinoic acid receptor-beta	Gene	5915
31938062	1426	1433	RARbeta	Gene	5915
31938062	1455	1464	GSK-3beta	Gene	2932
31938062	1527	1546	retinoid X receptor	Gene	6256
31938062	1548	1556	RXRalpha	Gene	6256
31938062	1563	1571	RARalpha	Gene	5914
31938062	1575	1582	RARbeta	Gene	5915
31938062	1622	1631	GSK-3beta	Gene	2932
31938062	1640	1648	retinoid	Chemical	MESH:D012176
31938062	1672	1681	sorafenib	Chemical	MESH:D000077157
31938062	1687	1690	HCC	Disease	MESH:D006528
31938062	1715	1724	GSK-3beta	Gene	2932
31938062	1728	1738	tideglusib	Chemical	MESH:C520571
31938062	1754	1762	9-cis-RA	Chemical	-
31938062	1778	1787	sorafenib	Chemical	MESH:D000077157
31938062	1801	1806	tumor	Disease	MESH:D009369
31938062	1863	1870	RARbeta	Gene	5915
31938062	1874	1893	tideglusib/9-cis-RA	Chemical	-
31938062	1942	1951	sorafenib	Chemical	MESH:D000077157
31938062	2004	2011	RARbeta	Gene	5915
31938062	2056	2065	GSK-3beta	Gene	2932
31938062	2084	2092	retinoid	Chemical	MESH:D012176
31938062	2134	2143	sorafenib	Chemical	MESH:D000077157
31938062	2147	2150	HCC	Disease	MESH:D006528
31938062	2162	2171	GSK-3beta	Gene	2932
31938062	2204	2207	HCC	Disease	MESH:D006528
31938062	Association	MESH:D012176	2932
31938062	Negative_Correlation	MESH:C520571	2932
31938062	Association	MESH:D009369	2932
31938062	Association	2932	5914
31938062	Association	MESH:D009369	5915
31938062	Association	MESH:D000077157	5915
31938062	Negative_Correlation	MESH:D000077157	2932
31938062	Negative_Correlation	MESH:C520571	MESH:D006528
31938062	Bind	5914	5915
31938062	Negative_Correlation	MESH:D000077157	MESH:D006528
31938062	Negative_Correlation	MESH:C520571	MESH:D000077157
31938062	Negative_Correlation	2932	5915
31938062	Association	MESH:D012176	MESH:D006528
31938062	Association	2932	6256
31938062	Bind	5914	6256
31938062	Bind	5915	6256
31938062	Association	MESH:D006528	2932
31938062	Negative_Correlation	MESH:C520571	MESH:D009369

